News

Celon Pharma at Top Picks by Trigon Investor Conference

On January 21, 2021, representatives of the Company’s Management Board will take part in the Top Picks by Trigon conference. Celon Pharma was among 21 companies recommended by Trigon DM in 2021.

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting.  In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »

Celon Pharma at Jefferies Virtual London Healthcare Conference

The Company’s representatives will take part in the largest pharmaceutical conference in Europe. Maciej Wieczorek, CEO of Celon Pharma S.A.: We are increasing the presence of our products abroad, building a strong position in the segment of inhalation products on the global pharmaceutical market; we are observing that companies from around the world are takingRead more »

The experts agree. The targeted drug against COVID currently developed by Celon Pharma might change the course of the disease.

Thanks to its cutting-edge, innovative approach, Celon Pharma fast-tracks confirmation of the efficacy of its treatment against SARS-COV-2. The new therapeutic approach designed by scientists at Celon Pharma combines the previously dispersed possible responses to the threat brought about by SARS-COV-2. That approach assumes shortening of the infection duration in affected patients and significant limitationRead more »